An interventional study of Biguanide, DPP4 inhibitors, SGLT2 inhibitors in Abdominal Obesity and Type 2 Diabetes, sponsored by Metabolic Research Unit. Status unknown at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-09.
Sponsored by Metabolic Research Unit · Not applicable, Interventional, and Treatment
Weight control is an essential part of treatment for type 2 diabetes (T2D) patients. Weight loss is associated with decreased haemoglobin A1c (A1c) levels. In particular, visceral fat is accompanied by more alterations in glucose and lipid metabolism. Quantification of visceral fat with bioimpedance (BIA) is closely related to measurement with computed axial tomography. Different available oral antidiabetics cause weight loss and total body fat (biguanides, DPP-4 inhibitors and SGLT-2 inhibitors), but it has only been shown that SLGT2 inhibitors decrease visceral fat. Therefore, the aim of this study is to determine whether there is a difference in the amount of visceral fat measured with BIA in T2D patients between three oral antidiabetic regimens after twelve weeks of treatment, to compare the effect on visceral fat between metformin, DPP4 inhibitors and SGLT2 inhibitors.
9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's planned enrollment of 30 is below the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →This is the only study on the registry with Metabolic Research Unit as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Metformin 1.7-2.5mg per day during twelve weeks
Drug: Biguanide, DPP4 inhibitors, SGLT2 inhibitors
Metformin 1.7-2.5mg per day plus Linagliptin 5mg per day or Sitagliptin 50-100mg per day
Drug: Biguanide, DPP4 inhibitors, SGLT2 inhibitors
Metformin 1.7-2.5mg per day plus Empaglifozin 10-25mg per day or Dapaglifozin 10mg per day
Drug: Biguanide, DPP4 inhibitors, SGLT2 inhibitors
Oral antidiabetic treatment during twelve weeks
Change from baseline in visceral fat measured by bioimpedance in kg at weet twelve
Bioimpedance is a confident method to measured visceral fat
Time frame: Baseline and week twelve
Change from baseline in A1c level at week twelve
Glycated hemoglobin percentage is the most reliable method to explain glycemic control in type 2 diabetes patients
Time frame: Baseline and week twelve
Plan to share: Undecided
This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.